NCT06491862Recruiting
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 11 Jun 2024
- Start date
- 25 Jul 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT06491862
What you commit to
- Study type: Observational
- Planned participants: 250
- From 25 Jul 2024 to the primary completion date, 31 Dec 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with evidence of other primary malignancies (except basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both study cohorts.
Other illness
- Patients who participated in a clinical investigational study for the treatment of any cancer, including NSCLC, or any early access program from 2018 onwards.
Who the study is looking for
- Confirmed diagnosis of non-squamous NSCLC, Stage IIIB/IIIC incurable or IV/M1.
- Age ≥ 18 years at diagnosis of advanced/metastatic disease.
- AGA Cohort: Presence of actionable mutations and all of the following:
- failure of platinum-based chemotherapy,
- failure of ≥ 1 line of approved target therapy or no targeted therapy available at the clinic,
- additional systemic treatment after platinum + target therapy combination.
- Non-AGA Cohort: Absence of actionable mutations and all of the following:
- failure of platinum-based chemotherapy,
- failure of immunotherapy concurrent or sequential to platinum,
- additional systemic treatment after platinum + immunotherapy combination.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Natal | Brazil | Recruiting |
| - Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Not yet recruiting |
| - Coordinator of this site? Confirm its status | São José do Rio Preto | Brazil | Not yet recruiting |
| - Coordinator of this site? Confirm its status | São Paulo | Brazil | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.